JP2004512814A - ペプチドおよび核酸組成物を使用する、ヒトパピローマウイルスに対する細胞性免疫応答の誘導 - Google Patents

ペプチドおよび核酸組成物を使用する、ヒトパピローマウイルスに対する細胞性免疫応答の誘導 Download PDF

Info

Publication number
JP2004512814A
JP2004512814A JP2001543143A JP2001543143A JP2004512814A JP 2004512814 A JP2004512814 A JP 2004512814A JP 2001543143 A JP2001543143 A JP 2001543143A JP 2001543143 A JP2001543143 A JP 2001543143A JP 2004512814 A JP2004512814 A JP 2004512814A
Authority
JP
Japan
Prior art keywords
peptide
epitope
hla
epitopes
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001543143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004512814A5 (https=
Inventor
セッテ，　アレッサンドロ
シドニー，　ジョン
サウスウッド，　スコット
チェスナット，　ロバート
セリス，　エステバン
グレイ，　ホワード　エム．
Original Assignee
エピミューン　インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピミューン　インコーポレイテッド filed Critical エピミューン　インコーポレイテッド
Publication of JP2004512814A publication Critical patent/JP2004512814A/ja
Publication of JP2004512814A5 publication Critical patent/JP2004512814A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2001543143A 1999-12-10 2000-12-11 ペプチドおよび核酸組成物を使用する、ヒトパピローマウイルスに対する細胞性免疫応答の誘導 Pending JP2004512814A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17270599P 1999-12-10 1999-12-10
US09/641,528 US7026443B1 (en) 1999-12-10 2000-08-15 Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
PCT/US2000/033549 WO2001041799A1 (en) 1999-12-10 2000-12-11 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions

Publications (2)

Publication Number Publication Date
JP2004512814A true JP2004512814A (ja) 2004-04-30
JP2004512814A5 JP2004512814A5 (https=) 2005-01-20

Family

ID=26868370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001543143A Pending JP2004512814A (ja) 1999-12-10 2000-12-11 ペプチドおよび核酸組成物を使用する、ヒトパピローマウイルスに対する細胞性免疫応答の誘導

Country Status (7)

Country Link
US (4) US7026443B1 (https=)
EP (1) EP1246644A4 (https=)
JP (1) JP2004512814A (https=)
AU (3) AU2258201A (https=)
CA (1) CA2393960C (https=)
MX (1) MXPA02005639A (https=)
WO (1) WO2001041799A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509911A (ja) * 2015-03-16 2018-04-12 マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ−ゲマインシャフト Ｍｈｃ細胞ライブラリーを用いる、新規の免疫原性ｔ細胞エピトープの検出方法および新規の抗原特異的ｔ細胞受容体の単離方法
JP2020536489A (ja) * 2017-08-16 2020-12-17 オックスフォード ユニバーシティ イノベーション リミテッドＯｘｆｏｒｄ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ Ｈｐｖワクチン

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
CA2425648A1 (en) 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7842480B2 (en) * 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US8067535B2 (en) * 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
WO2004067032A2 (en) * 2003-01-24 2004-08-12 University Of Massachusetts Medical Center Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes
US7981601B2 (en) * 2003-08-01 2011-07-19 Institute Of Basic Medical Sciences Method of preparing polyepitope chimeric gene vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US10941353B2 (en) 2004-04-28 2021-03-09 Hydrocarbon Technology & Innovation, Llc Methods and mixing systems for introducing catalyst precursor into heavy oil feedstock
KR101354740B1 (ko) 2004-04-28 2014-01-22 헤드워터스 헤비 오일, 엘엘씨 에뷸레이트 베드 하이드로프로세싱 방법 및 시스템 및기존의 에뷸레이트 베드 시스템을 개량하는 방법
US7517446B2 (en) * 2004-04-28 2009-04-14 Headwaters Heavy Oil, Llc Fixed bed hydroprocessing methods and systems and methods for upgrading an existing fixed bed system
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
EP1877087B1 (en) * 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20070218080A1 (en) * 2006-03-14 2007-09-20 Mackay Memorial Hospital Peptide antigen of human papillomavirus type 16 and application thereof
CA3057039C (en) * 2006-07-28 2023-02-28 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
WO2008021296A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
US8969542B2 (en) * 2007-05-31 2015-03-03 Genimmune N.V. HPV polyepitope constructs and uses thereof
WO2009021063A2 (en) * 2007-08-06 2009-02-12 The Regents Of The University Of California Composition and method of use for hcv immunization
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US8652482B2 (en) * 2007-10-03 2014-02-18 The Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
US8722851B2 (en) * 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
WO2009093251A2 (en) * 2008-01-24 2009-07-30 Gavish-Galilee Bio Applications Ltd Reovirus vaccine based on sigma c protein sequence
KR20090103571A (ko) * 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
WO2009149021A2 (en) 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
WO2009146523A1 (en) 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
EP2344191A4 (en) * 2008-09-02 2013-02-13 Antigen Express Inc HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
EP2993183B1 (en) * 2010-02-16 2020-02-26 Österreichische Akademie der Wissenschaften Anti-hpv e7 antibodies
US20120045413A1 (en) * 2010-04-09 2012-02-23 Mayumi Nakagawa Human papilloma virus peptide-specific T-cell response for treatment of warts
TWI507413B (zh) * 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
US8663964B2 (en) * 2011-07-20 2014-03-04 Tamir Biotechnology, Inc. Methods of treating human papillomavirus
US9790440B2 (en) 2011-09-23 2017-10-17 Headwaters Technology Innovation Group, Inc. Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
US8715681B2 (en) * 2012-02-02 2014-05-06 Hengsun Pharmaceutical Technology Co. Ltd. Minimal motifs of linear B-cell epitopes in L1 protein from human papillomavirus type 58 and their applications
WO2014007584A1 (en) * 2012-07-05 2014-01-09 Gwangju Institute Of Science And Technology Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban
EP2872532A4 (en) 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
US9644157B2 (en) 2012-07-30 2017-05-09 Headwaters Heavy Oil, Llc Methods and systems for upgrading heavy oil using catalytic hydrocracking and thermal coking
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
CN104004067B (zh) * 2013-02-22 2017-09-01 艾托金生物医药（苏州）有限公司 用于检测抗人乳头瘤病毒抗体的抗原及相关免疫检测试剂盒
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
EP2883550A1 (en) 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
KR101677940B1 (ko) * 2014-07-18 2016-11-21 연세대학교 산학협력단 인유두종바이러스 e7 절단된 펩타이드의 자궁경부암 진단 및 치료 용도
KR101680567B1 (ko) 2014-07-09 2016-11-29 연세대학교 산학협력단 인유두종바이러스 펩타이드의 자궁경부암 진단 및 치료 용도
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
EP3261666A4 (en) * 2015-02-26 2018-10-31 Bioventures, Llc Recall antigen for promoting t-helper type 1 response
SG10201911292SA (en) 2015-06-15 2020-02-27 Tamir Biotechnology Inc Pharmaceuticals for treatment of viral infections of the eye
US11414607B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor with increased production rate of converted products
US11414608B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor used with opportunity feedstocks
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
US11421164B2 (en) 2016-06-08 2022-08-23 Hydrocarbon Technology & Innovation, Llc Dual catalyst system for ebullated bed upgrading to produce improved quality vacuum residue product
WO2018039205A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
US11732203B2 (en) 2017-03-02 2023-08-22 Hydrocarbon Technology & Innovation, Llc Ebullated bed reactor upgraded to produce sediment that causes less equipment fouling
KR102505534B1 (ko) 2017-03-02 2023-03-02 하이드로카본 테크놀로지 앤 이노베이션, 엘엘씨 오염 침전물이 적은 업그레이드된 에뷸레이티드 베드 반응기
CA3058807A1 (en) * 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
JP7385556B2 (ja) 2017-09-01 2023-11-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用
EP3700575A1 (en) 2017-10-24 2020-09-02 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
WO2019145792A1 (en) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Hpv immunotherapy
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CA3057131C (en) 2018-10-17 2024-04-23 Hydrocarbon Technology And Innovation, Llc Upgraded ebullated bed reactor with no recycle buildup of asphaltenes in vacuum bottoms
CN109517033B (zh) * 2018-10-31 2021-02-05 深圳凯联健康生物科技有限公司 活性肽、重组载体、重组细胞、抗炎组合物及其制备方法和应用
CN111440811A (zh) * 2019-02-25 2020-07-24 武汉凯德维斯生物技术有限公司 同时靶向hpv16 l1及hpv16 e5e6e7的宫颈癌疫苗及其制备方法
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
CN111153967B (zh) * 2019-12-16 2023-04-07 温州医科大学 一种对hpv16 e5蛋白特异性结合的多肽及其应用
CN115867295A (zh) * 2020-03-23 2023-03-28 昆士兰医学研究所理事会 用于靶向hpv感染细胞的组合物和方法
CN113984947B (zh) * 2020-07-27 2024-05-17 中国食品药品检定研究院 测定9价hpv疫苗中抗原蛋白含量的特异性肽段及方法
CN114539363B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
US12584918B2 (en) * 2021-09-23 2026-03-24 Arizona Board Of Regents On Behalf Of Arizona State University Multiplexed lateral flow assay for detection of HPV associated cancer
US12497569B2 (en) 2022-05-26 2025-12-16 Hydrocarbon Technology & Innovation, Llc Method and system for mixing catalyst precursor into heavy oil using a high boiling hydrocarbon diluent
CN120424179A (zh) * 2025-05-06 2025-08-05 扬州大学 人乳头瘤病毒l1蛋白的b细胞保守表位肽及其在感染早期抗体检测中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04227000A (ja) * 1990-05-10 1992-08-17 Behringwerke Ag ヒトパピローマウイルス１８のタンパク質における血清反応性エピトープ
JPH06501542A (ja) * 1990-05-11 1994-02-17 ユーロ―ディアグノスティカ　アー・ベー 診断用免疫検定法に有用なヒト乳頭腫ウイルス１，５，６，８，１１，１６，１８，３１，３３および５６の合成ペプチド類
JPH10506796A (ja) * 1994-10-06 1998-07-07 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、アズ レプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ パピローマウイルス様キメラ粒子
JPH10510989A (ja) * 1994-12-20 1998-10-27 シーエスエル、リミテッド ヒトパピローマウイルス抗原の変異体
US5871998A (en) * 1992-09-03 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
JPH11507507A (ja) * 1995-06-07 1999-07-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ パピローマ・ウイルス感染診断の方法、キットおよび組成物
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
FI83662C (fi) 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.
US4487715A (en) * 1982-07-09 1984-12-11 The Regents Of The University Of California Method of conjugating oligopeptides
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
FR2591227B1 (fr) 1985-12-06 1988-11-10 Pasteur Institut Peptides capables d'inhiber les interactions entre les virus lav et les lymphocytes t4, produits qui en sont derives et leurs applications
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5200320A (en) 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
US5180806A (en) 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1238343B (it) 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
US5753233A (en) 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
AU8305491A (en) 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
JPH06507384A (ja) 1991-01-22 1994-08-25 ザ　イミューン　レスポンス　コーポレイション 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
EP0534615B1 (en) 1991-08-26 2001-01-03 Epimmune Inc. HLA-restricted hepatitis B virus CTL epitopes
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
WO1993021324A1 (en) 1992-04-21 1993-10-28 Institut Pasteur Recombinant mutants for inducing specific immune responses
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US20020177694A1 (en) 1996-01-23 2002-11-28 Alessandro Sette Hla binding peptides and their uses
US20040096445A1 (en) * 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US20020098197A1 (en) 1994-07-21 2002-07-25 Alesandro Sette Hla binding peptides and their uses
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
BR9406652A (pt) 1993-03-05 1996-09-10 Cytel Corp Composição
US5853755A (en) 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
US6413935B1 (en) * 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US20050049197A1 (en) * 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AU5849796A (en) 1994-12-27 1996-08-07 United Biomedical Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
JP4108126B2 (ja) 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
ATE512666T1 (de) 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
EP1230268B1 (en) * 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040157273A1 (en) * 2001-08-22 2004-08-12 John Sidney Subunit vaccines with a2 supermotifs

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04227000A (ja) * 1990-05-10 1992-08-17 Behringwerke Ag ヒトパピローマウイルス１８のタンパク質における血清反応性エピトープ
JPH06501542A (ja) * 1990-05-11 1994-02-17 ユーロ―ディアグノスティカ　アー・ベー 診断用免疫検定法に有用なヒト乳頭腫ウイルス１，５，６，８，１１，１６，１８，３１，３３および５６の合成ペプチド類
US5871998A (en) * 1992-09-03 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5985610A (en) * 1992-09-03 1999-11-16 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
JPH10506796A (ja) * 1994-10-06 1998-07-07 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、アズ レプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ パピローマウイルス様キメラ粒子
JPH10510989A (ja) * 1994-12-20 1998-10-27 シーエスエル、リミテッド ヒトパピローマウイルス抗原の変異体
JPH11507507A (ja) * 1995-06-07 1999-07-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ パピローマ・ウイルス感染診断の方法、キットおよび組成物
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010048360, ＶＩＲＯＬＯＧＹ, 1985, ｖｏｌ．１４５, ｐｐ．１８１−１８５ *
JPN6010048364, ＶＩＲＯＬＯＧＹ, 199909, ｖｏｌ．２６２, ｐｐ．３４４−３５４ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509911A (ja) * 2015-03-16 2018-04-12 マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ−ゲマインシャフト Ｍｈｃ細胞ライブラリーを用いる、新規の免疫原性ｔ細胞エピトープの検出方法および新規の抗原特異的ｔ細胞受容体の単離方法
JP2020536489A (ja) * 2017-08-16 2020-12-17 オックスフォード ユニバーシティ イノベーション リミテッドＯｘｆｏｒｄ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ Ｈｐｖワクチン
US12064477B2 (en) 2017-08-16 2024-08-20 Oxford University Innovation Limited HPV vaccine
JP7551495B2 (ja) 2017-08-16 2024-09-17 オックスフォード ユニバーシティ イノベーション リミテッド Ｈｐｖワクチン

Also Published As

Publication number Publication date
AU2006200654A2 (en) 2006-03-23
EP1246644A4 (en) 2005-05-11
CA2393960C (en) 2015-06-02
US7026443B1 (en) 2006-04-11
MXPA02005639A (es) 2004-09-10
AU2258201A (en) 2001-06-18
CA2393960A1 (en) 2001-06-14
WO2001041799A1 (en) 2001-06-14
AU2006200654A1 (en) 2006-03-23
US20070053922A1 (en) 2007-03-08
AU2006200654C1 (en) 2010-03-04
US20130017253A1 (en) 2013-01-17
US20090214632A1 (en) 2009-08-27
US7572882B2 (en) 2009-08-11
EP1246644A1 (en) 2002-10-09
AU2006200654B2 (en) 2009-07-30
AU2009225354A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
AU2006200654B2 (en) Inducing cellular immune responses to human papilloma virus using peptide and nucleic acid compositions
JP4873810B2 (ja) ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導
US20040037843A1 (en) Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US20070014810A1 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
JP2003530083A (ja) ペプチドおよび核酸組成物を使用する、ＨＥＲ２／ｎｅｕに対する細胞性免疫応答の誘導
US20070020327A1 (en) Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
JP2004508320A (ja) ペプチドおよび核酸組成物を用いるｂ型肝炎ウイルスに対する細胞性免疫応答の誘導
US20040121946A9 (en) Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
JP2003509465A (ja) ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
JP2004500059A (ja) ペプチドおよび核酸組成物を使用する、癌胎児性抗原に対する細胞性免疫応答の誘導
JP2003517310A (ja) ペプチドおよび核酸組成物を使用する、ｍａｇｅ２／３に対する細胞性免疫応答の誘導
US20040048790A1 (en) Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
US20040053822A1 (en) Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
US20050196403A1 (en) Inducing cellular immune responses to p53 using peptide and nucleic acid compositions

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110131